OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Trent on Research Efforts in Bone and Soft Tissue Sarcomas

May 1st 2020

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Dr. Chen on Rapid Research Autopsy in Rare Cancer

May 1st 2020

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

Dr. O'Regan on Breast Cancer Treatment Considerations During the COVID-19 Crisis

May 1st 2020

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

Alternate Delivery Models for Genetic Counseling in Prostate Cancer

April 30th 2020

Alanna K. Rahm, PhD, MS, discusses alternate delivery models for genetic counseling in prostate cancer.

Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPC

April 30th 2020

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

Dr. Oh on Adapting the PRINT Trial Model to Other Settings in Prostate Cancer

April 30th 2020

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

April 30th 2020

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Dr. Cuellar on the Pharmacoeconomic Benefits of Biosimilars

April 30th 2020

Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.

Dr. Abraham on Potential Symptoms of TGCT

April 30th 2020

John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.

Dr. Ferris on Ongoing Research With STING Agonists/Checkpoint Inhibitors in Head and Neck Cancer

April 30th 2020

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.

Dr. Sawyers on the Negative Results of the IMbassador250 Trial in mCRPC

April 30th 2020

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Dr. Chang on Efforts to Improve Quality of Life in Prostate Cancer

April 30th 2020

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Dr. Armstrong on the utility of PARP Inhibitors in Mutated Prostate Cancer

April 30th 2020

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer Management

April 29th 2020

Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.

Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPC

April 29th 2020

Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Beltran on the Limitations of Tissue Biopsies Versus Liquid Biopsies in CRPC-NE

April 29th 2020

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.

Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

April 29th 2020

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Dr. Kudchadkar on the Biological Differences Between Ocular and Cutaneous Melanoma

April 29th 2020

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Dr. Daver on Stem Cell Transplant Considerations in Hematologic Malignancies in Light of COVID-19

April 29th 2020

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Dr. Ferris on a Trial Testing ADU-S100/MIW815/Pembrolizumab in Head and Neck Cancer

April 28th 2020

Robert L. Ferris, MD, PhD, director of University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Hillman Professor of Oncology, associate vice chancellor for cancer research, professor of otolaryngology, immunology, and radiation oncology, co-director, Tumor Microenvironment Center, UPMC Hillman Cancer Center, discusses a clinical trial testing ADU-S100/MIW815 plus pembrolizumab (Keytruda) in patients with head and neck cancer.